432 related articles for article (PubMed ID: 29525278)
21. In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6.
von Teichman BF; Dungu B; Smit TK
Vaccine; 2010 Sep; 28(39):6505-17. PubMed ID: 20638456
[TBL] [Abstract][Full Text] [Related]
22. Western immunoblotting as a method for the detection of African horse sickness virus protein-specific antibodies: differentiation between infected and vaccinated horses.
Bougrine SI; Fihri OF; Fehri MM
Arch Virol Suppl; 1998; 14():329-36. PubMed ID: 9785518
[TBL] [Abstract][Full Text] [Related]
23. African Horse Sickness: A Review of Current Understanding and Vaccine Development.
Dennis SJ; Meyers AE; Hitzeroth II; Rybicki EP
Viruses; 2019 Sep; 11(9):. PubMed ID: 31514299
[TBL] [Abstract][Full Text] [Related]
24. Oral susceptibility of South African Culicoides species to live-attenuated serotype-specific vaccine strains of African horse sickness virus (AHSV).
Paweska JT; Prinsloo S; Venter GJ
Med Vet Entomol; 2003 Dec; 17(4):436-47. PubMed ID: 14651659
[TBL] [Abstract][Full Text] [Related]
25. Serological and virological responses in mules and donkeys following inoculation with African horse sickness virus serotype 4.
el Hasnaoui H; el Harrak M; Zientara S; Laviada M; Hamblin C
Arch Virol Suppl; 1998; 14():29-36. PubMed ID: 9785493
[TBL] [Abstract][Full Text] [Related]
26. Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines.
Crafford JE; Lourens CW; Smit TK; Gardner IA; MacLachlan NJ; Guthrie AJ
Vaccine; 2014 Jun; 32(29):3611-6. PubMed ID: 24814557
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses.
Dennis SJ; O'Kennedy MM; Rutkowska D; Tsekoa T; Lourens CW; Hitzeroth II; Meyers AE; Rybicki EP
Vet Res; 2018 Oct; 49(1):105. PubMed ID: 30309390
[TBL] [Abstract][Full Text] [Related]
28. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
Feenstra F; Pap JS; van Rijn PA
Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
[TBL] [Abstract][Full Text] [Related]
29. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
[TBL] [Abstract][Full Text] [Related]
30. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
Roy P; Bishop DH; Howard S; Aitchison H; Erasmus B
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2053-7. PubMed ID: 8811002
[TBL] [Abstract][Full Text] [Related]
31. The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses.
Laviada MD; Roy P; Sánchez-Vizcaíno JM; Casal JI
Virus Res; 1995 Oct; 38(2-3):205-18. PubMed ID: 8578859
[TBL] [Abstract][Full Text] [Related]
32. African horse sickness.
Zientara S; Weyer CT; Lecollinet S
Rev Sci Tech; 2015 Aug; 34(2):315-27. PubMed ID: 26601437
[TBL] [Abstract][Full Text] [Related]
33. Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel Disabled Infectious Single Animal (DISA) vaccine for Bluetongue.
Tacken MGJ; Daus FJ; Feenstra F; van Gennip RGP; van Rijn PA
Vaccine; 2015 Oct; 33(42):5539-5545. PubMed ID: 26387435
[TBL] [Abstract][Full Text] [Related]
34. Requirements and comparative analysis of reverse genetics for bluetongue virus (BTV) and African horse sickness virus (AHSV).
van Rijn PA; van de Water SG; Feenstra F; van Gennip RG
Virol J; 2016 Jul; 13():119. PubMed ID: 27368544
[TBL] [Abstract][Full Text] [Related]
35. Phylogenetic analysis of African horse sickness virus segment 10: sequence variation, virulence characteristics and cell exit.
Martin LA; Meyer AJ; O'Hara RS; Fu H; Mellor PS; Knowles NJ; Mertens PP
Arch Virol Suppl; 1998; 14():281-93. PubMed ID: 9785513
[TBL] [Abstract][Full Text] [Related]
36. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.
Aksular M; Calvo-Pinilla E; Marín-López A; Ortego J; Chambers AC; King LA; Castillo-Olivares J
Vaccine; 2018 Nov; 36(46):7003-7010. PubMed ID: 30309744
[TBL] [Abstract][Full Text] [Related]
37. African horse sickness in The Gambia: circulation of a live-attenuated vaccine-derived strain.
Oura CA; Ivens PA; Bachanek-Bankowska K; Bin-Tarif A; Jallow DB; Sailleau C; Maan S; Mertens PC; Batten CA
Epidemiol Infect; 2012 Mar; 140(3):462-5. PubMed ID: 21733265
[TBL] [Abstract][Full Text] [Related]
38. Bluetongue Disabled Infectious Single Animal (DISA) vaccine: Studies on the optimal route and dose in sheep.
van Rijn PA; Daus FJ; Maris-Veldhuis MA; Feenstra F; van Gennip RGP
Vaccine; 2017 Jan; 35(2):231-237. PubMed ID: 27916409
[TBL] [Abstract][Full Text] [Related]
39. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.
Castillo-Olivares J; Calvo-Pinilla E; Casanova I; Bachanek-Bankowska K; Chiam R; Maan S; Nieto JM; Ortego J; Mertens PP
PLoS One; 2011 Jan; 6(1):e16503. PubMed ID: 21298069
[TBL] [Abstract][Full Text] [Related]
40. Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes.
Sullivan E; Lecollinet S; Kerviel A; Hue E; Pronost S; Beck C; Dumarest M; Zientara S; Roy P
Vaccine; 2021 May; 39(23):3161-3168. PubMed ID: 33958224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
